Obesity

FDA Accepts Supplement Application for Wegovy (Semaglutide) by Novo

The FDA has accepted a supplemental application for Wegovy (semaglutide), indicating ongoing development and potential label expansion.

FDA Accepts Supplement Application for Wegovy (Semaglutide) by Novo

The FDA has accepted a supplemental application for Wegovy (semaglutide) submitted by Novo.

AZD1043 Study Launches to Assess Safety and Pharmacokinetics in Overweight and Obese Adults

A clinical trial is underway to evaluate the safety, tolerability, and pharmacokinetics of AZD1043 in healthy adults with overweight and obesity.

FDA Accepts Supplement Application for Phentermine Hydrochloride and Topiramate

The FDA has accepted a supplemental application for Phentermine Hydrochloride and Topiramate submitted by Actavis Labs.

Study on Bariatric Embolization Before Sleeve Gastrectomy in Super Obese Patients

The study evaluates the safety and effectiveness of bariatric embolization prior to sleeve gastrectomy in patients with severe obesity.

Adhera Health's ACDP-O Study Targets Obesity in Youth with Chronic Conditions

Adhera Health is conducting a feasibility study on its family-centered digital health intervention for obesity in adolescents and young adults with chronic conditions.

Safety and Effectiveness Study of IGBalloon for Obesity Treatment Initiated

A prospective study is underway to assess the safety and effectiveness of the IGBalloon in treating obesity with 20 participants.

Alnylam's ALN-2232 Undergoing Evaluation for Obesity Treatment

A clinical trial is evaluating ALN-2232 for safety, efficacy, and pharmacokinetics in patients with obesity, including combination therapy with tirzepatide.

MHRA Issues Guidance on Safe Use of GLP-1 Weight Loss Medicines

The MHRA emphasizes the importance of safe usage of GLP-1 medicines amid rising demand for weight-loss solutions.

Alveus Therapeutics initiates ALV-100 study for obesity and Type 2 Diabetes

Alveus Therapeutics is conducting a study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of ALV-100 in overweight/obese participants, including those with Type 2 Diabetes.

Lilly's retatrutide shows significant weight loss in Phase 3 obesity trials

In Phase 3 trials TRIUMPH-2 and TRIUMPH-3, retatrutide demonstrated significant weight loss in adults with obesity and type 2 diabetes, and severe obesity with cardiovascular disease.

FDA Accepts Supplement for SAXENDA (Liraglutide) by Novo

The FDA has accepted a supplemental application for SAXENDA, an obesity treatment containing liraglutide.

FDA grants AP status for Phentermine Hydrochloride and Topiramate by Dr. Reddy's Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a combination of Phentermine Hydrochloride and Topiramate submitted by Dr. Reddy's Labs.

Hoffmann-La Roche Evaluates Petrelintide and Enicepatide in Obesity Trial

A dose-finding study is underway to assess the safety and efficacy of petrelintide combined with enicepatide in adults with obesity.

Phase III Study of DA-302168S for Overweight/Obesity Initiated in China

A Phase III clinical trial for DA-302168S has been initiated to evaluate its efficacy and safety in overweight or obese participants.

ZnO Nanoparticles from Pomegranate Husk Show Promise in Obesity Management

Zinc oxide nanoparticles synthesized from pomegranate husk exhibit significant antioxidant and enzyme inhibition properties, comparable to established anti-obesity drugs.

Study on GLP-1 Agonists and Lifestyle Changes in Obese Adolescents

A study is assessing the impact of GLP-1 receptor agonists combined with lifestyle changes on organ health in adolescents with severe obesity.

Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation

The Allurion Gastric Balloon may cause serious complications, including gastric outlet obstruction, small bowel obstruction, and gastric perforation.

Study on GLP-1 RAs and Exercise Training in Obesity Patients Launched

A 2-year randomized clinical trial will evaluate the effects of GLP-1 RA therapy combined with exercise training on muscle and metabolic outcomes in obesity.

FDA Approves Supplemental Application for Wegovy (Semaglutide)

The FDA has approved a supplemental application for Wegovy, a drug containing semaglutide, submitted by Novo.

FDA grants supplemental approval for Phentermine Hydrochloride and Topiramate

The FDA has granted supplemental approval for the combination of Phentermine Hydrochloride and Topiramate under application ANDA204982.

Study on Brain Stimulation's Impact on Food Intake and Weight Loss

This clinical trial investigates the effects of transcranial direct current stimulation (TDCS) on food intake and weight loss in obese individuals over four weeks.

Novo Nordisk's NNC0487-0111 Trial Targets Obesity in Sleep Apnoea Patients

Novo Nordisk is investigating the efficacy and safety of NNC0487-0111 in overweight or obese patients with obstructive sleep apnoea.

FDA Acceptance of QSYMIA Supplemental Application by VIVUS LLC

The FDA has accepted a supplemental application for QSYMIA, a combination of phentermine and topiramate, submitted by VIVUS LLC.

Vyvanse Evaluated for Weight Management in Children Aged 6-12

A clinical trial is underway to assess the efficacy of lisdexamfetamine combined with lifestyle therapy in children struggling with weight management.

Study on Bariatric Endoscopic Antral Myotomy (BEAM) for Obesity Underway

A pilot study is evaluating the safety and efficacy of Bariatric Endoscopic Antral Myotomy (BEAM) for weight loss.

Pilot Study on Behavioral Program for Weight Loss After GLP-1 Discontinuation

A pilot randomized factorial trial is assessing a multi-component behavioral intervention for weight loss maintenance after discontinuation of GLP-1 and anti-obesity medications.

AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM

AstraZeneca is conducting two pivotal Phase III studies to evaluate the efficacy and safety of elecoglipron in adults with obesity or overweight, with and without T2DM.

Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program

The Medicare GLP-1 Bridge program will provide access to Lilly's obesity treatments, Foundayo and Zepbound, for eligible Medicare Part D patients starting July 1.

Eli Lilly's Eloralintide Trial Targets Insulin Sensitivity in Obesity

Eli Lilly is conducting a 35-week trial to evaluate eloralintide's effects on insulin sensitivity and metabolic health in overweight or obese participants.

Phase 2a Trial of KDS2010 in Obesity Shows Promising Efficacy and Safety Profile

Phase 1b Study of CX11 Tablets for Obesity by Corxel Pharmaceuticals

Corxel Pharmaceuticals is conducting Phase 1b study to evaluate the safety and tolerability of CX11 tablets in participants with obesity or overweight.

Semaglutide tablet approved in the UK for weight loss

The semaglutide tablet has received approval from the MHRA for weight loss and management in the UK.

Study on GLP-1 and Lifestyle Interventions in Pediatric Obesity Management

A study led by the University of Minnesota aims to evaluate the effectiveness of health behavior and lifestyle treatment in conjunction with GLP-1 medications for adolescents with obesity.

Eli Lilly's Orforglipron Study in Adolescents with Obesity Underway

Eli Lilly is conducting a study to evaluate the efficacy and safety of orforglipron in adolescents with obesity or related comorbidities.

Eli Lilly's Tirzepatide Study Targets Adolescents with Obesity and Comorbidities

Eli Lilly is conducting a study to evaluate tirzepatide's effects on weight and cardiovascular risk in adolescents with obesity.

Roche to Present Phase II Data on Enicepatide and Petrelintide at ADA 2026

Roche will present new Phase II data for enicepatide and petrelintide in obesity at the ADA Scientific Sessions.

CVS Caremark to cover Foundayo and Zepbound, enhancing access for obesity treatment

CVS Caremark will cover Foundayo starting June 1 and Zepbound from October 1, allowing eligible patients to pay as low as $25 monthly.

Foundayo shows significant weight reduction in older adults with obesity in new analysis

Foundayo (orforglipron) demonstrated up to 13% body weight reduction in adults aged 65 and older with obesity.

Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial

In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs (28.3%) over 80 weeks.

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management

Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial

In the TRIUMPH-1 trial, retatrutide led to an average weight loss of 70.3 lbs and significant reductions in knee osteoarthritis pain.